GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM

GCKR 介导的信号转导和白血病转化

基本信息

  • 批准号:
    2896405
  • 负责人:
  • 金额:
    $ 7.4万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    1998
  • 资助国家:
    美国
  • 起止时间:
    1998-09-30 至 2001-09-29
  • 项目状态:
    已结题

项目摘要

DESCRIPTION (Applicant's Description): Chronic myelogenous leukemia (CML) is a clonal myeloproliferative disorder of the primitive hematopoietic stem cell. CML accounts for approximately 25% of all adult leukemia. The BCR-ABL oncogene probably represents the initiating event in nearly all CML, although additional genetic events are required for the full malignant phenotype. The recently described serine-threonine kinases GCK and GCKR are known to activate the pathway that is thought to mediate the transforming ability of BCR-ABL. Specifically, based on work that is to be presented under Preliminary Studies, the applicants hypothesize that GCKR specifically associates with, and is activated by, BCR-ABL and is likely a critical element in BCR-ABL's transforming potential. Based on this they propose to: 1) examine the basic elements and requirements that mediate the association between GCKR and BCR-ABL; 2) examine the functional consequences of the BCR-ABL relationship with GCKR; 3) assess the in vivo transforming potential of GCK and GCKR. Elucidating the role of GCKR in BCR-ABL mediated transformation will allow for a better understanding of the mechanism of oncogenic transformation, and thus allow for the development of improved treatment and prognostication strategies for CML. The applicant's training in molecular biology, immunology, and clinical oncology, in addition to his direct experience with the initial cloning of GCKR put him in the unique position to pursue the studies proposed here.
描述(申请人描述):

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

JOSEPH M TUSCANO其他文献

JOSEPH M TUSCANO的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('JOSEPH M TUSCANO', 18)}}的其他基金

Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
发酵小麦胚芽蛋白;机制、免疫学和临床前犬研究
  • 批准号:
    10421263
  • 财政年份:
    2019
  • 资助金额:
    $ 7.4万
  • 项目类别:
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
发酵小麦胚芽蛋白;机制、免疫学和临床前犬研究
  • 批准号:
    9779443
  • 财政年份:
    2019
  • 资助金额:
    $ 7.4万
  • 项目类别:
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
发酵小麦胚芽蛋白;机制、免疫学和临床前犬研究
  • 批准号:
    10616508
  • 财政年份:
    2019
  • 资助金额:
    $ 7.4万
  • 项目类别:
Fermented wheat germ proteins;mechanistic, immunologic and pre-clinical canine studies
发酵小麦胚芽蛋白;机制、免疫学和临床前犬研究
  • 批准号:
    10057226
  • 财政年份:
    2019
  • 资助金额:
    $ 7.4万
  • 项目类别:
CD22-targeted Therapeutics for the Treatment of Lung Cancer
用于治疗肺癌的 CD22 靶向疗法
  • 批准号:
    8597910
  • 财政年份:
    2012
  • 资助金额:
    $ 7.4万
  • 项目类别:
CD22-targeted Therapeutics for the Treatment of Lung Cancer
用于治疗肺癌的 CD22 靶向疗法
  • 批准号:
    8244390
  • 财政年份:
    2012
  • 资助金额:
    $ 7.4万
  • 项目类别:
CD22-targeted Therapeutics for the Treatment of Lung Cancer
用于治疗肺癌的 CD22 靶向疗法
  • 批准号:
    8764678
  • 财政年份:
    2012
  • 资助金额:
    $ 7.4万
  • 项目类别:
PHASE II TRIAL OF BEVACIZUMAB VS BEVACIZUMAB, THALIDOMIDE FOR RELAPSED/REFRACTOR
贝伐珠单抗与贝伐珠单抗、沙利度胺治疗复发/折射患者的 II 期试验
  • 批准号:
    6975684
  • 财政年份:
    2004
  • 资助金额:
    $ 7.4万
  • 项目类别:
GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
GCKR 介导的信号转导和白血病转化
  • 批准号:
    6173226
  • 财政年份:
    1998
  • 资助金额:
    $ 7.4万
  • 项目类别:
GCKR MEDIATED SIGNAL TRANSDUCTION AND LEUKEMIC TRANSFORM
GCKR 介导的信号转导和白血病转化
  • 批准号:
    2564624
  • 财政年份:
    1998
  • 资助金额:
    $ 7.4万
  • 项目类别:

相似海外基金

REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056554
  • 财政年份:
    1990
  • 资助金额:
    $ 7.4万
  • 项目类别:
REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056556
  • 财政年份:
    1989
  • 资助金额:
    $ 7.4万
  • 项目类别:
REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056555
  • 财政年份:
    1988
  • 资助金额:
    $ 7.4万
  • 项目类别:
REPRODUCTION AND ENDOCRINE LEVELS IN THE ATHYMIC MOUSE
无胸腺小鼠的繁殖和内分泌水平
  • 批准号:
    3056553
  • 财政年份:
    1987
  • 资助金额:
    $ 7.4万
  • 项目类别:
The Athymic Mouse As a Model For the Study of Keloids
无胸腺小鼠作为瘢痕疙瘩研究的模型
  • 批准号:
    7816691
  • 财政年份:
    1978
  • 资助金额:
    $ 7.4万
  • 项目类别:
    Standard Grant
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了